Melanoma CRE

Melanoma CRE

Melanoma CRE: Implementation Science and Sentinel Lymph Node Biopsy Project

This project is funded by a National Health and Medical Research Council Grant.


Project main description

Established in 2018, the NHMRC-funded Centre of Research Excellence in Melanoma (CRE Melanoma) is a strategic collaboration of clinicians and researchers from melanoma centres in New South Wales (Melanoma Institute Australia) and Victoria (Peter MacCallum Cancer Centre; Victorian Melanoma Service), Australia, and implementation scientists from the Australian Institute of Health Innovation, Macquarie University, Sydney. This multidisciplinary partnership combines leading clinical expertise in melanoma diagnosis and treatment with methodological expertise in epidemiology, bioinformatics, economics, qualitative research and implementation science.

Project members - Macquarie University

 
Professor
Professor
Research Fellow
    

Project members - external

  • Associate Professor Anne Cust, Cancer Epidemiology and Prevention Research, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney; Melanoma Institute Australia (MIA), Sydney
  • Professor Richard Scolyer, Melanoma Institute Australia (MIA), Sydney; Sydney Medical School, The University of Sydney, Sydney
  • Professor John Kelly, Victorian Melanoma Service, The Alfred, Melbourne; Department of Medicine, Monash University, Melbourne
  • Associate Professor Rachael Morton, NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia; Melanoma Institute Australia (MIA), Sydney
  • Professor Andrew Spillane, Melanoma Institute Australia (MIA), Sydney; Sydney Medical School, The University of Sydney, Sydney
  • Associate Professor Robyn Saw, Melanoma Institute Australia (MIA), Sydney; Sydney Medical School, The University of Sydney, Sydney
  • Professor Michael Henderson, Peter MacCallum Cancer Centre; Melbourne Medical School, University of Melbourne, Melbourne
  • Professor Jean Yang, School of Mathematics and Statistics, Charles Perkins Centre, The University of Sydney, Sydney

Partners:

Centre for Research Excellence in Melanoma

Primary objectives

The CRE Melanoma is tasked with three primary objectives: pursuing collaborative research; developing capacity; and ensuring translation of research outcomes into policy and practice. It will achieve this in three core areas:

Core 1: identifying and managing people at high risk of developing melanoma;

Core 2: optimising management of people with curable, early-stage melanoma; and,

Core 3: psychosocial care, survivorship and the patient experience.

Core 2 projects: sentinel lymph node (SLN) biopsy

Optimum treatment for melanoma, whether surgery, radiation or drug-based, depends on adequate assessment of the risk that the melanoma has spread to nearby lymph nodes. Sentinel lymph node (SLN) biopsy is a procedure used in staging melanoma patients. The SLN biopsy project is examining the factors influencing doctors' and patients' decision to have, or not to have, a SLN biopsy and developing strategies to ensure the procedure is used to greatest benefit.

Publications

Hogden A., Churruca K., Rapport F. and Gillatt D. Appraising risk in    active surveillance of localised prostate cancer, Health Expectations. Accepted 26 April 2019. Published online 17 May 2019, doi: 10.1111/hex.12912.

Rapport F., Khanom A., Doel MA., Hutchings HA., Bierbaum M., Hogden A., Shih P., Braithwaite J. and Clement C. Women’s perceptions of journeying towards an unknown future with breast cancer: the “Lives at Risk” study. Qualitative Health Research. Online September 22nd 2017. doi: 10/1177/1049732317730569.  Published 2018: 28(1), 30-46.

Rapport F., Clay-Williams R., Churruca K., Shih P., Hogden A. and Braithwaite J. The struggle of translating Science into Action: Foundational Concepts of Implementation Science. Journal of Evaluation in Clinical Practice. 24: 117-126. doi: 10.1111/jep.12741.

Content owner: Australian Institute of Health Innovation Last updated: 25 Jun 2019 8:06am

Back to the top of this page